Piramal Pharma Ltd (PPLPHARMA)
₹181.27
Mkt cap
₹24,133 Cr
P/E ratio
—
P/B
2.95
Div yield
0.08%
ROE
−3.83%
ROCE
2.52%
EPS (TTM)
—
Book value
₹61
52W range
133–212
Sector
Healthcare
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]
Health check
Mixed
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−14.37% from high₹181
₹133+36.02% from low₹212
Current
₹181.27
Prev close
₹181.21
Day
+0.03%
Price performance
1D
+0.03%
1W
+1.34%
1M
+8.10%
3M
+9.55%
6M
+14.87%
1Y
−16.42%
YTD
+1.56%
Financials
FRevenue, profit & margin
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,163.58 | 1,748.85 | 1,911.38 | 1,958.57 | 2,552.36 | 1,951.14 | 2,241.75 | 2,204.22 | 2,754.07 | 1,933.71 | 2,043.72 | 2,139.87 | 2,751.77 | |
| Expenses | 1,812.31 | 1,616.53 | 1,645.74 | 1,690.20 | 2,022.43 | 1,746.65 | 1,900.14 | 1,866.48 | 2,193.08 | 1,827.01 | 1,885.03 | 1,944.14 | 2,291.26 | |
| Operating Profit | 351.27 | 132.32 | 265.64 | 268.37 | 529.93 | 204.49 | 341.61 | 337.74 | 560.99 | 106.70 | 158.69 | 195.73 | 460.51 | |
| OPM % | 16.24% | 7.57% | 13.90% | 13.70% | 20.76% | 10.48% | 15.24% | 15.32% | 20.37% | 5.52% | 7.76% | 9.15% | 16.74% | |
| Other Income | 32.28 | 52.70 | 68.30 | 43.19 | 7.90 | 41.94 | 78.37 | 29.18 | 58.25 | 97.71 | 80.39 | 12.39 | -116.14 | |
| Interest | 104.25 | 118.52 | 109.87 | 105.88 | 114.22 | 106.96 | 107.64 | 103.31 | 103.68 | 86.15 | 82.42 | 89.24 | 82.99 | |
| Depreciation | 184.41 | 173.61 | 184.51 | 186.32 | 196.13 | 184.55 | 192.22 | 196.81 | 242.76 | 197.28 | 202.84 | 212.74 | 218.38 | |
| Profit before tax | 94.89 | -107.11 | 39.56 | 19.36 | 227.48 | -45.08 | 120.12 | 66.80 | 272.80 | -79.02 | -46.18 | -93.86 | 43.00 | |
| Tax % | 47.19% | -7.96% | 87.31% | 47.78% | 55.48% | 96.63% | 81.19% | 94.49% | 43.73% | 3.39% | 114.85% | 45.10% | 120.53% | |
| Net Profit | 50.11 | -98.58 | 5.02 | 10.11 | 101.27 | -88.64 | 22.59 | 3.68 | 153.50 | -81.70 | -99.22 | -136.19 | -8.83 | |
| EPS in Rs | 0.38 | -0.75 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
29 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.35% · closed higher next day 6 of last 15
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 3 Aug '23◦ | 28 Oct '23◦ | 30 Jan '24◦ | 10 May '24◦ | 26 Jul '24 | 23 Oct '24◦ | 28 Jan '25◦ | 14 May '25◦ | 28 Jul '25◦ | 5 Nov '25◦ | 29 Jan '26 | 28 Apr '26◦ |
| Earnings day | −2.41% | +3.19% | +3.78% | +2.49% | +0.13% | +17.36% | +9.49% | −4.76% | +0.62% | −0.54% | −0.18% | −2.63% |
| +1 day | −3.92% | +12.97% | −0.47% | −1.03% | +2.39% | +12.13% | +5.81% | −6.47% | −1.46% | −0.63% | +0.47% | −1.58% |
| +5 days | −7.14% | +17.30% | +0.25% | −0.63% | +4.79% | +23.16% | +3.88% | −5.81% | −5.29% | −3.28% | +3.01% | +11.71% |
| +15 days | −4.68% | +29.62% | −2.95% | −0.56% | +10.29% | +15.49% | −9.56% | −5.00% | −6.15% | −7.00% | +5.90% | +7.06% |
| +30 days | −4.44% | +36.81% | −14.06% | +6.18% | +30.69% | +18.81% | −7.65% | −8.24% | −2.05% | −16.91% | −9.19% | −0.38% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202634.80%Promoter
Promoters34.80%0.05
FIIs12.51%17.66
DIIs14.57%1.04
Public37.62%18.61
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Piramal Pharma | ₹181.27 | — | 24,133 | 0.08% | −9 | −25.01% | 2,752 | −0.08% | 2.52% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports4
Concall transcripts45
TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026TranscriptNov 2025PPTNov 2025TranscriptOct 2025PPTJul 2025RECJul 2025PPTJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptOct 2024PPTOct 2024PPTSep 2024TranscriptJul 2024PPTJul 2024RECJul 2024PPTJul 2024TranscriptMay 2024
Credit ratings6
Announcements5
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat. 6h - 24 July 2026: Ahmedabad facilities temporarily suspended due to flooding; operations expected to normalize in days.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 Jul - Piramal Pharma to host Q1 FY2027 earnings call on 30 July 2026, 9:30-10:15 AM IST.Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June, 2026. 20 Jul - Board meets on 29 July 2026 to approve Q1 FY27 unaudited standalone and consolidated results; trading window closed till 31 July.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 17 Jul - HDFC Mutual Fund reduced Piramal Pharma stake to 7.015% after selling 2.005% on July 14, 2026.Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 9 Jul - US FDA issued EIR, closing inspection at Sellersville manufacturing facility successfully.